Skip to content
All Sections
Subscribe Now
84°F
Wednesday, August 21st 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
84°F
Wednesday, August 21st 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Pike Outlets shooting
Driver's licenses to go mobile
Long Beach's Olympic moment
Walker killed by dogs
Joe Jost's turns 100 ð
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BeiGene
< Previous
1
2
3
Next >
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
August 07, 2024
From
BeiGene
Via
Business Wire
Tickers
BGNE
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
March 13, 2024
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
October 13, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
August 31, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
July 21, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
July 12, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
July 10, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
July 07, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
June 15, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
June 09, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
May 25, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Present at Upcoming Investor Conferences
May 24, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
May 17, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
May 06, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
April 26, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
April 25, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
April 20, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Expands Presence in Latin America With Opening of Brazil Office
April 13, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
March 30, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
March 21, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
February 24, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
February 24, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
February 03, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Present at Upcoming Investor Conferences
February 01, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
January 19, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
January 19, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
January 18, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
January 17, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023
From
BeiGene
Via
Business Wire
Tickers
BGNE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close